Seeking Alpha

The FDA has again rejected United Therapeutics' (UTHR) Treprostinil oral treatment for treating...

The FDA has again rejected United Therapeutics' (UTHR) Treprostinil oral treatment for treating for high blood pressure. United Therapeutics intends to immediately request an "end of review" meeting with the FDA to discuss the rejection. Shares -6.3% premarket. (previous) (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)